Results 251 to 260 of about 205,750 (304)

Neoadjuvant Chemoradiotherapy and Neoadjuvant Chemotherapy

2017
Rectal cancer is a challenging disease to treat, and its optimal management requires a multidisciplinary approach with involvement of surgical, medical, and radiation oncologists.
Mohamed E. Salem, John L. Marshall
openaire   +1 more source

Neoadjuvant chemotherapy in ovarian cancer

Expert Review of Anticancer Therapy, 2004
Primary radical tumor debulking followed by platinum/taxane-based chemotherapy is considered standard for advanced stage ovarian carcinomas. The extent of postoperative residual disease is the most important prognostic factor. However, complete tumor resection is achieved in only 40-50% of advanced ovarian cancers.
Tjoung-Won, Park, Walther C, Kuhn
openaire   +2 more sources

Neoadjuvant Chemotherapy of Breast Cancer

The American Surgeon, 2004
The use of neoadjuvant chemotherapy in the treatment of breast cancer has been evolving during the past two decades. Fisher's group accomplished the scientific rationale in mouse models in the 1970s. The Milan group was the first to use neoadjuvant therapy in locally advanced breast cancer and also determined that adjuvant sequential doxorubicin with ...
Christopher A, Garces, William G, Cance
openaire   +2 more sources

Neoadjuvant chemotherapy for bladder cancer

Urologic Oncology: Seminars and Original Investigations, 2003
While it is now clear that chemotherapy can contribute to improved outcome for some patients with muscle invasive bladder cancer, selection criteria for this very heterogeneous disease are lacking. The authors make an appeal for a biologically (in contrast to anatomically) based staging system, and urge that perioperative chemotherapy be given with ...
Randall, Millikan, Arlene, Siefker-Radtke, H Barton, Grossman   +2 more
openaire   +2 more sources

Neoadjuvant chemotherapy in cervix cancer

1994
Despite the decrease in the incidence of cervix cancer over the last decade, 13 500 new cases and 4400 deaths were expected in the United States in 1992 [1]. Accessibility of the cervix for cytologic evaluation via the Pap smear, visual inspection by colposcopy, and histologic evaluation by biopsy have made cervical cacer a preventable and potentially ...
P R, Dottino, R A, Segna
openaire   +2 more sources

The Role of Neoadjuvant Chemotherapy in NSCLC

Chest, 1996
Neoadjuvant chemotherapy to reduce tumor size before surgery or radiologic treatment is now a feasible option in the treatment of non-small cell lung cancer (NSCLC). Patients in clinical stage IIIA N2 of the disease who were previously a poor prognostic subset when treated with surgery are now being treated with neoadjuvant chemotherapy, followed by ...
openaire   +2 more sources

Neoadjuvant chemotherapy for bladder cancer

World Journal of Urology, 2006
The 30-45% failure rate after radical cystoprostatectomy mandates that we explore and optimize multimodal therapy to achieve better disease control in these patients. Cisplatin-based multi-agent combination chemotherapy has been used with success in metastatic disease and has therefore also been introduced in patients with high-risk but non-metastatic ...
Peter C, Black, Gordon A, Brown, H Barton, Grossman, Colin P, Dinney   +3 more
openaire   +2 more sources

[Neoadjuvant chemotherapy in gastric carcinoma].

Annali italiani di chirurgia, 2001
A complete surgical resection currently represents the only curative treatment option for gastric carcinoma, but as regards locally advanced cancer the possibility of local or distant recurrence remains extremely high even following a R0 resection. As far as T3-4/N+ tumors are concerned, unsatisfying results of surgery alone have stressed the need for ...
D'Ugo D., Persiani R., Pende V., Picciocchi A.   +3 more
openaire   +3 more sources

Neoadjuvant Chemotherapy for Nonmetastatic Osteosarcoma of the Extremities

Clinical Orthopaedics and Related Research, 1991
Between September 1986 and December 1988, 125 patients with osteosarcoma of the extremities entered the second neoadjuvant study at the authors' institution. Patients received preoperatively two cycles of methotrexate (MTX) intravenously, followed by cisplatinum (CDP) intraarterially, plus adriamycin (ADM) intravenously.
BACCI G, PICCI P, PIGNATTI G, DECRISTOFARO R, DALLARI D, AVELLA M, MANFRINI M, MARANGOLO M, FERRUZZI A, MERCURI M, RUGGIERI P, BIAGINI R, CAPANNA, RODOLFO, FERRARI S, PRASAD R, CAMPANACCI M.   +15 more
openaire   +4 more sources

Benefits of Neoadjuvant Chemotherapy in NSCLC

Chest, 1996
There is a significant potential benefit for induction chemotherapy in the management of non-small cell lung cancer (NSCLC). The real extent of such benefit is difficult to assess on the basis of available data owing to the intrinsic limitations of phase II studies.
openaire   +2 more sources